In vivo Heparan Sulfate Treatment Alters the Immune Response of Normal and LLC-Bearing Mice

REFERENCES

• Adam J.K., Odhav B, Bhoola K.D. Immune responses in cancer. Pharmacol. Ther 2003; 99: 113–132, [CSA]
   PubMed Web of Science ®Google Scholar
• Agarwal A., Rani M., Saha G.K., Valarmathi T.M., Bahadur S., Mohanti B.K., Das S.N. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol. Invest 2003; 32: 17–30, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Antonia S.J., Extermann M., Flavell R.A. Immunologic nonresponsiveness to tumors. Crit. Rev. Oncog 1998; 9: 35–41, [CSA]
   PubMed Web of Science ®Google Scholar
• Batra R.K., Lin Y., Sharma S., Dohadwala M., Luo J., Pold M., Dubinett S.M. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res 2003; 63: 642–646, [CSA]
   PubMed Web of Science ®Google Scholar
• Caux C., Massacrier C., Vanbervliet B., Barthelemy C., Liu Y.J., Banchereau J. Interleukin 10 inhibits T-cell alloreaction induced by human dendritic cells. Int Immunol 1994; 6: 1177–1185, [CSA]
   PubMed Web of Science ®Google Scholar
• Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S.M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995; 55: 3847–3853, [CSA]
   PubMed Web of Science ®Google Scholar
• Kavanaugh D.Y., Carbone D.P. Immunologic dysfunction in cancer. Hematol. Oncol. Clin. North Am 1996; 10: 927–951, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lathers D.M., Achille N.J., Young M.R. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum. Immunol 2003; 64: 1160–1166, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Young M.R., Petruzzelli G.J., Kolesiak K., Achille N., Lathers D.M., Gabrilovich D.I. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34+progenitor cells. Hum. Immunol 2001; 62: 332–341, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rashid R.M., Achille N.J., Lee J.M., Lathers D.M., Young M.R. Decreased T-Cell Proliferation and Skewed Immune Responses in LLC-Bearing Mice. JEPTO 2005; 24: 175–192, [CROSSREF], [CSA]
   Google Scholar
• Young M.R., Wright M.A., Vellody K., Lathers D.M. Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3. Int J Immunopharmacol 1999; 21: 675–688, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Young M.R., Lathers D.M. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int. J. Immunopharmacol 1999; 21: 241–252, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Young M.R., Wright M.A., Lathers D.M., Messingham K.A. Increased resistance to apoptosis by bone marrow CD34+progenitor cells from tumor-bearing mice. Int. J. Cancer 1999; 82: 609–615, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ishida K., Wierzba M.K., Teruya T., Simizu S., Osada H. Novel heparan sulfate mimetic compounds as antitumor agents. Chem. Biol 2004; 11: 367–377, [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Wrenshall L.E., Cerra F.B., Geller R.L., Carlson A., Bach F.H., Platt J.L. Heparan sulfate augments the splenocyte response to mitogenic stimuli. Transplant Proc 1991; 23: 325, [CSA]
   PubMed Web of Science ®Google Scholar
• Wrenshall L.E., Cerra F.B., Carlson A., Bach F.H., Platt J.L. Regulation of murine splenocyte responses by heparan sulfate. J. Immunol 1991; 147: 455–459, [CSA]
   PubMed Web of Science ®Google Scholar
• Wrenshall L.E., Platt J.L., Stevens E.T., Wight T.N., Miller J.D. Propagation and control of T-cell responses by heparan sulfate-bound IL-2. J Immunol 2003; 170: 5470–5474, [CSA]
   PubMed Web of Science ®Google Scholar
• Wrenshall L.E., Stevens R.B., Cerra F.B., Platt J.L. Modulation of macrophage and B cell function by glycosaminoglycans. J Leukoc Biol 1999; 66: 391–400, [CSA]
   PubMed Web of Science ®Google Scholar
• Steinbrink K., Graulich E., Kubsch S., Knop J., Enk A.H. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99(7)2468–2476, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fayad L., Keating M.J., Reuben J.M., O'Brien S., Lee B.N., Lerner S., Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256–263, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sarris A.H., Kliche K.O., Pethambaram P., Preti A., Tucker S., Jackow C., Messina O., Pugh W., Hagemeister F.B., McLaughlin P., Rodriguez M.A., Romaguera J., Fritsche H., Witzig T., Duvic M., Andreeff M., Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol 1999; 10: 433–440, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pawelec G. Tumour escape from the immune response. Cancer Immunol. Immunother 2004; 53: 843, [CSA]
   Google Scholar
• Wrenshall L.E., Cerra F.B., Rubinstein P., Platt J.L. Regulation by heparan sulfate and interleukin 1 alpha of the ontogenic expression of T-cell receptor, CD4, and CD8 in developing thymus. Hum. Immunol 1993; 38: 165–171, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wrenshall L.E., Carlson A., Cerra F.B., Platt J.L. Modulation of cytolytic T-cell responses by heparan sulfate. Transplantation 1994; 57: 1087–1094, [CSA]
   PubMed Web of Science ®Google Scholar
• Wrenshall L.E., Platt J.L. Regulation of T-cell homeostasis by heparan sulfate-bound IL-2. J Immunol 1999; 163: 3793–3800, [CSA]
   PubMed Web of Science ®Google Scholar
• Wrenshall L. Role of the microenvironment in immune responses to transplantation. Springer Semin Immunopathol 2003; 25: 199–213, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yamamoto N., Zou J.P., Li X.F., Takenaka H., Noda S., Fujii T., Ono S., Kobayashi Y., Mukaida N., Matsushima K., et al. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T-cells or macrophages in the tumor-bearing state. J Immunol 1995; 154: 2281–2290, [CSA]
   PubMed Web of Science ®Google Scholar
• Yoshitomi Y., Nakanishi H., Kusano Y., Munesue S., Oguri K., Tatematsu M., Yamashina I., Okayama M. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 2004; 207: 165–174, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J., Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729–777, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Xu J., Park P.W., Kheradmand F., Corry D.B. Endogenous attenuation of allergic lung inflammation by syndecan-1. J. Immunol 2005; 174: 5758–5765, [CSA]
   PubMed Web of Science ®Google Scholar
• Kodama J., Shinyo Y., Hasengaowa H.K., Kusumoto T., Seki N., Nakamura K., Hongo A., Hiramatsu Y. Loss of basement membrane heparan sulfate expression is associated with pelvic lymph node metastasis in invasive cervical cancer. Oncol. Rep 2005; 14: 89–92, [CSA]
   PubMed Web of Science ®Google Scholar